Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) announced that CEO Laurence Reid, Ph.D., will join a fireside chat at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 10:00 a.m. ET in New York City. This event will explore the company's efforts in developing innovative treatments aimed at restoring hearing and balance. A live webcast will be available on the Decibel Therapeutics website, with an archived version accessible for 90 days post-event. Decibel Therapeutics focuses on gene therapies for congenital and acquired hearing disorders.

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.

A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

FAQ

When is the Jefferies Cell and Genetic Medicine Summit where Decibel Therapeutics will participate?

The Jefferies Cell and Genetic Medicine Summit is on September 30, 2022, at 10:00 a.m. ET.

Who is the CEO of Decibel Therapeutics participating in the fireside chat?

Laurence Reid, Ph.D., is the CEO of Decibel Therapeutics participating in the fireside chat.

How can I access the live webcast for Decibel Therapeutics' fireside chat?

The live webcast can be accessed on the Investors section of the Decibel Therapeutics website.

What is the focus of Decibel Therapeutics?

Decibel Therapeutics is focused on discovering and developing treatments to restore hearing and balance.

What is DB-OTO in Decibel Therapeutics' pipeline?

DB-OTO is a lead gene therapy program aimed at treating congenital, monogenic hearing loss.